Prevention of schizophrenia: Can it be achieved?

CNS Drugs

Volumn 19, Issue 3, 2005, Pages 193-206

  Lee, Cheng ^a   McGlashan, Thomas H ^a   Woods, Scott W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

CAREGIVER; DEVELOPMENTAL DISORDER; DISABILITY; DISEASE COURSE; DRUG RESEARCH; EDUCATION PROGRAM; FAMILY; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; MENTAL DISEASE; MORBIDITY; NERVE CELL DIFFERENTIATION; NEURODEVELOPMENTAL DISORDER; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RARE DISEASE; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL DISABILITY; SOCIETY; TREATMENT INDICATION; VALIDATION PROCESS;

DISEASE PROGRESSION; HUMANS; SCHIZOPHRENIA;

EID: 16244368756     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519030-00002     Document Type: Review

References (166)

1. Warner R, de Girolamo G. Epidemiology of mental disorders and psychosocial problems: schizophrenia. Geneva: World Health Organization; 1995
2. Aleman A, Kahn RS, Selten J-P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 2003; 60 (6): 565-71
3. Hafner H, Maurer K, Loffler W, et al. The epidemiology of early schizophrenia: influence of age and gender on onset and early course. Br J Psychiatry 1994; 164 Suppl. 23: 29-38
4. Loranger AW. Sex differences in age of onset of schizophrenia. Arch Gen Psychiatry 1984; 41: 157-61
5. Frangou S, Murray RM. Schizophrenia. London: Martin Dunitz, 1996
6. Kupfer DJ, Sartorius N. The usefulness and use of second-generation antipsychotic medications [abstract]. Curr Opin Psychiatry 2002; 15 Suppl. 1: S17
7. Rice DP, Miller LS. The economics burden of schizophrenia: conceptual and methodology issues and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of mental health economics and health policy. Vol. 1: schizophrenia. New York: John Wiley and Sons, 1996: 321-34
8. Caplan G. Principles of preventive psychiatry. New York: Basic Books, 1964
9. Mrazek PJ, Haggerty RJ, editors. Reducing risks for mental disorders: frontiers for preventive intervention research. Washington, DC: National Academy Press, 1994
10. Zubin J, Spring B. Vulnerability: a new view of schizophrenia. J Abnorm Psychol 1977; 86: 103-26
11. Kestenbaum CJ. Children at risk from schizophrenia. Am J Psychother 1980; 34 (2): 164-77
12. Gottesman II. Shields J. Schizophrenia and genetics: a twin study vantage point. New York: Academic Press, 1972
13. Gottesman II. Schizophrenia genesis: the origin of madness. New York: WH Freeman and Company, 1991
14. Kendler KS, McGuire M, Gruenberg AM, et al. Clinical heterogeneity in schizophrenia and the pattern of psychopathology in relatives: results from an epidemiologically based family study. Acta Psychiatr Scand 1994; 89: 294-300
15. Sham PC, Jones P, Russell A, et al. Age at onset, sex, and familial psychiatric morbidity in schizophrenia: Camberwell Collaborative Psychosis Study. Br J Psychiatry 1994; 165: 466-73
16. Murray RM, Lewis SW, Reveley AM. Towards an aetiological classification of schizophrenia. Lancet 1985; 8436: 1023-6
17. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? BMJ 1987; 295: 681-2
18. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44 (7): 660-9
19. Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995; 346: 552-7
20. Weinberger DR. Schizophrenia as a neurodevelopmental disorder. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. London: Blackwood, 1995; 295-323
21. McClure RK, Weinberger DR. The neurodevelopmental hypothesis of schizophrenia: a review of the evidence. In: Breier A, Tran PV, Herrea JM, et al., editors. Current issues in the psychopharmacology of schizophrenia. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 27-56
22. Hollister JM, Laing P, Mednick SA. Rhesus incompatibility as a risk factor for schizophrenia in male adults. Arch Gen Psychiatry 1996; 53: 19-24
23. Kendall RE, Juszczak E, Cole SK. Obstetrical complications and schizophrenia: a case control study based on standardized obstetrical records. Br J Psychiatry 1996; 168: 556-61
24. Jones PB, Rantakallio PR, Hartikainen AL, et al. Schizophrenia as a long term outcome of pregnancy, delivery and perinatal complications: a 28 year follow-up of the 1966 North Finland general population birth cohort. Am J Psychiatry 1998; 155 (3): 355-64
25. Dalman C, Alleback PA, Cullberg J, et al. Obstetrical complications and the risk of schizophrenia. Arch Gen Psychiatry 1999; 56: 234-40
26. Susser E, Neugebauer R, Heok HW. Schizophrenia after perinatal famine: further evidence. Arch Gen Psychiatry 1996; 53: 25-31
27. Brown AS, Schaefer CA, Wyatt RJ, et al. Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr Bull 2000; 26 (2): 287-95
28. Mednick S, Machon RA, Huttunen MO. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988; 45: 189-92
29. O'Callaghan E, Sham P, Takei N, et al. Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet 1991; 337: 1248-50
30. Sham P, O'Callaghan E, Takei N, et al. Schizophrenia following prenatal exposure to influenza epidemics between 1939-1960. Br J Psychiatry 1992; 160: 461-6
31. O'Reilly RL. Viruses and schizophrenia. Aust N Z J Psychiatry 1994; 28 (2): 222-8
32. McGrath J, Murray RM. Risk factors for schizophrenia: from conception to birth. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science, 1995: 187-205
33. Cutting J. The psychology of schizophrenia. Edinburgh: Churchill Livingstone, 1985
34. O'Callaghan E, Larkin C, Kinsella A, et al. Familial, obstetric, and other clinical correlates of minor physical anomalies in schizophrenia. Am J Psychiatry 1991; 148: 479-83
35. Green MF, Bracha HS, Satz P, et al. Preliminary evidence for an association between minor physical anomalies and second trimester neurodevelopment in schizophrenia. Psychiatry Res 1994; 53 (2): 119-27
36. McGrath J, van Os J, Hoyos C, et al. Minor physical anomalies in the functional psychosis: associations with clinical and putative aetiological variables. Schizophr Res 1995; 18: 9-20
37. Davis JO, Bracha HS. Prenatal growth markers in schizophrenia: a monozygotic co-twin control study. Am J Psychiatry 1996; 153 (9): 1166-72
38. Fananas L, van Os J, Murray RM. Dermatoglyphic a-b ridge count as a possible marker for developmental insult in schizophrenia: replication in two samples. Schizophr Res 1996; 20: 307-14
39. Jones PB, Rogers B, Murray RM, et al. Childhood development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994; 334: 1398-402
40. Jones PB, Done DJ. From birth to onset: a developmental perspective of schizophrenia in two national birth cohorts. In: Keshavan MS, Murray RM, editors. Neurodevelopment and adult psychopathology. Cambridge: Cambridge University Press, 1997: 119-36
41. Done DJ, Crow TJ, Johnstone EC, et al. Childhood antecedents of schizophrenia and affective illness. BMJ 1994; 309: 699-703
42. Chua SE, Murray RM. The neurodevelopmental theory of schizophrenia: evidence concerning structure and neuropsychology. Acta Neuropsychiatrica 1996; 8 (2): 25-34
43. Davies N, Russell A, Jones PB, et al. What characteristics of schizophrenia predate psychosis? J Psychiatr Res 1997; 32 (3-4): 121-31
44. Delisi LE, Hoff AL, Schwartz JE. Brain morphology in first episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study. Biol Psychiatry 1991; 129: 159-75
45. Degreef G, Ashtari M, Bogerts B, et al. Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry 1992; 49: 531-7
46. Woodruff PWR, Murray RM. The aetiology of brain abnormalities in schizophrenia. In: Ancill R, editor. Schizophrenia: exploring the spectrum of psychosis. Chichester: John Wiley, 1994: 95-144
47. Chua SE, McKenna PJ. Schizophrenia: a brain disease? A critical review of structural and functional cerebral abnormality in the disorder. Br J Psychiatry 1995; 166: 563-82
48. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia: a systematic review of volumetric magnetic resonance imaging studies. Br J Psychiatry 1998; 172: 110-20
49. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999; 122: 593-624
50. Zipursky RB, Lim KO, Sullivan EV, et al. Widespread cerebral gray matter volume deficits in schizophrenia. Arch Gen Psychiatry 1992; 49 (3): 195-205
51. Harvey I, Ron MA, Du Boulay G, et al. Reduction of cortical volume in schizophrenia on magnetic resonance imaging. Psychol Med 1993; 23 (3): 591-604
52. Lim K, Tew W, Koshner M, et al. Cortical grey matter volume deficit is present in first episode schizophrenia. Schizophr Res 1995; 15: 95-6
53. Pieri J, Gupta BK, Bagwell W, et al. MRI abnormalities in first episode schizophrenia: association in neurological impairment [abstract]. Schizophr Res 1995; 15: 90
54. Lim KO, Sullivan EV, Zipursky RB, et al. Cortical gray matter volume deficits in schizophrenia: a replication. Schizophr Res 1996; 20: 157-64
55. Wright IC, Ellison ZR, Sharma T, et al. Mapping of grey matter changes in schizophrenia. Schizophr Res 1999; 35: 1-14
56. Weinberger DR, DeLisi LE, Perman G, et al. Computed tomography scans in schizophreniform disorder and other acute psychiatric patients. Arch Gen Psychiatry 1982; 39: 778-83
57. Weinberger DR, Bigelow LB, Kleinman JE, et al. Cerebral ventricular enlargement in chronic schizophrenia: association with poor response to treatment. Arch Gen Psychiatry 1980; 37: 11-4
58. Nasrallah HA, Olson SC, McCalley WM, et al. Cerebral ventricular enlargement in schizophrenia: a preliminary follow-up study. Arch Gen Psychiatry 1986; 43 (2): 157-9
59. Illowsky B, Juliano DM, Bigelow LB, et al. Stability of CT scan findings in schizophrenia. J Neurol Neurosurg Psychiatry 1988; 51: 209-13
60. Vita A, Sacchetti E, Valvassori G, et al. Brain morphology in schizophrenia. Acta Psychiatr Scand 1988; 78: 618-21
61. Jaskiw GE, Juliano DM, Goldberg TE, et al. Cerebral ventricular enlargement in schizophreniform disorder does not progress: a seven year follow-up study. Schizophr Res 1994; 14: 23-8
62. Marsh L, Suddath RL, Higgins N, et al. Medial temporal lobe structures in schizophrenia: relationship of size to duration of illness. Schizophr Res 1994; 11 (3): 225-38
63. Vita A, Dieci M, Giobbio GM, et al. Time course of cerebral ventricular enlargement in schizophrenia supports the hypothesis of its neurodevelopmental nature. Schizophr Res 1997; 23: 25-30
64. Mathalon DH, Sullivan EV, Lim KO, et al. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001; 58 (2): 148-57
65. Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001; 98(20): 11650-5
66. Wood SJ, Velakoulis D, Smith DJ, et al. A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophr Res 2001; 52 (1-2): 37-46
67. Hass GL, Sweeney JA. Premorbid and onset features of first-episode schizophrenia. Schizophr Bull 1992; 18 (3): 373-86
68. Keshavan MS, Schooler NR. First-episode studies in schizophrenia: criteria and characterization. Schizophr Bull 1992; 18 (3): 491-513
69. Loebel AD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149(9): 1183-8
70. Beiser M, Erikson D, Fleming JAE, et al. Establishing the onset of psychotic illness. Am J Psychiatry 1993; 150: 1349-54
71. Olin SC, Mednick SA. Risk factors of psychosis: identifying vulnerable populations premorbidly. Schizophr Bull 1996; 22: 223-40
72. Hafner H, Maurer K, Loffler W, et al. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993; 162: 80-6
73. Jones P, Bebbington P, Foerster A, et al. Premorbid social underachievement in schizophrenia: results from the Camberwell Collaborative Psychosis Study. Br J Psychiatry 1993; 162: 65-71
74. Yung AR, McGorry PD. The initial prodrome ih psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry 1996; 30: 587-99
75. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996; 22: 353-70
76. Woods SW, Miller T, McGlashan TH. The 'prodromal' patient: both symptomatic and at-risk. CNS Spectrum 2001; 6 (3): 223-32
77. National Early Psychosis Project Clinical Guidelines Working Party, Australian clinical guidelines for early psychosis: National Early Psychosis Project. Melbourne: University of Melbourne, 1998
78. Birchwood M, Todd P, Jackson C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry Suppl 1998; 172 (33): 53-9
79. Geddes JR, Lawrie SM. Obstetric complications and schizophrenia. Br J Psychiatry 1995; 167: 786-93
80. Kelly RH, Danielsen BH, Golding JM, et al. Adequacy of prenatal care among women with psychiatric diagnoses giving birth in California in 1994 and 1995. Psychiatr Serv 1999; 50: 1584-90
81. Warner R. The prevention of schizophrenia: what interventions are safe and effective? Schizophr Bull 2001; 27 (4): 551-62
82. Davidson M, Reichenberg A, Rabinowitz J, et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 1999; 156: 1328-35
83. Jablensky A. Schizophrenia: the epidemiological horizon. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science, 1995: 206-52
84. Comblait BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994; 20: 31-46
85. Cornblatt BA, Obuchowski M. Attention and clinical symptoms in schizophrenia. Psychiatr Q 1997; 58; 655-60
86. Cornblatt BA. Predictors of schizophrenia and preventive intervention. In: Breier A, Tran PV, Herrea JM, et al., editors. Current issues in the psychopharmacology of schizophrenia. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 389-406
87. Cornblatt BA, Obuchowski M, Roberts S, et al. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999; 11: 487-508
88. DSM-III-R. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC; American Psychiatric Association, 1987
89. DSM-IV. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
90. Jackson HJ, McGorry PD, McKenzie D. The reliability of DSM-III prodromal symptoms in first-episode psychotic patients. Acta Psychiatr Scand 1994; 90: 375-8
91. Jackson HJ, McGorry PD, Dudgeon P. Prodromal symptoms of schizophrenia in first-episode psychosis: prevalence and specificity. Compr Psychiatry 1995; 36: 241-50
92. Hafner H, Riecher-Rossler A, Hambrect M, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Bull 1992; 6: 209-23
93. Heiz MI. Melville C. Relapse in schizophrenia. Am J Psychiatry 1980; 137: 801-5
94. Heinrichs DW, Carpenter WT. Prospective study of prodromal symptoms in schizophrenia relapse. Am J Psychiatry 1985; 142: 371-3
95. Subotnik KL, Nuechteilein KH. Prodromal signs and symptoms of schizophrenic relapse. J Abnorm Psychol 1988; 97: 405-12
96. Biichwood M, Smith J, MacMillan F, et al. Predicting relapse in schizophrenia: the development and implementation of early signs monitoring system using patients and families as observers: a preliminary investigation. Psychol Med 1989; 19: 649-56
97. Tarrier N, Barrowclough C, Bamrah JS. Prodromal signs of relapse in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1991; 26: 157-61
98. Birchwood M. Early intervention in schizophrenia: theoretical background and clinical strategies. Br J Clin Psychol 1992; 31: 257-78
99. McGorry PD, Yung AR, Phillips LJ. Closing in: what features predict the onset of first-episode psychosis within an ultra-high-risk group? In: Zipursky RB, Schulz SC, editors. The early stages of schizophrenia. Washington, DC: American Psychiatric Publishing Inc., 2002: 3-32
100. Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22: 283-303
101. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis: a step towards indicated prevention of schizophrenia. Br J Psychiatry 1998; 172 (33): 14-20
102. McGorry PD. Preventive interventions in the prepsychotic phase: panacea, pipedreams. or Pandora's box? Presented at Second International Conference on Early Psychosis; 2000 Apr 1; New York
103. Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. Psychiatr Q 1999; 70: 273-87
104. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002; 159: 863-5
105. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996; 22: 201-22
106. McGlashan TH. Early detection and intervention with schizophrenia: research. Schizophr Bull 1996; 22: 327-46
107. Hass GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 1998; 13 Suppl. 13: 31-4
108. Larsen TK, Johannessen JO, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis. Br J Psychiatry 1998; 172 Suppl. 33: 40-5
109. Johnstone EC, MacMillan J, Crow T, et al. The Northwich Park First Episodes of Schizophrenia: III. Short-term outcome in trial entrants and trial eligible patients. Br J Psychiatry 1986: 148: 128-33
110. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996; 22: 241-56
111. Larsen TK, McGlashan TH, Johannessen JO, et al. First-episode schizophrenia: II. Premorbid patterns by gender. Schizophr Bull 1996; 22: 257-69
112. Drake RJ, Clifford JH, Akhtar S, et al. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry 2000; 177: 511-515
113. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50 (11): 884-97
114. Falloon IRH. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992; 55: 4-15
115. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59 (10): 921-8
116. McGlashan TH, Zipursky RB, Perkins D. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design. Schizophr Res 2003; 61: 7-18
117. Woods SW, Breier A, Zipursky RB, et al. Randomized trial of olanzapine vs placebo in the symptomatic acute treatment of patients meeting criteria for the schizophrenic prodrome. Biol Psychiatry 2003; 54: 453-64
118. McGlashan TH, Zipursky RB, Perkins DO. Olanzapine versus PBO for the schizophrenic prodrome: one-year results [poster]. 156th American Psychiatric Association 2003 Annual Meeting; 2003 May 21; San Francisco
119. Cornblatt B, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001; 51 (1): 31-8
120. McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001; 51 (1): 17-29
121. Larsen TK, Bechdolf A, Birchwood M. The concept of schizophrenia and phase-specific treatment: cognitive-behavioral treatment in pre-psychosis and in nonresponders. J Am Acad Psychoanal Dyn Psychiatry 2003; 31 (1): 209-28
122. Miller TJ, Zipursky RB, Perkins DO, et al. The PRIME North America randomized double-blind clinical trial of a olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: II. Baseline characteristics of the "prodromal" sample. Schizophr Res 2003; 61: 19-30
123. Preda A, Miller TJ, Rosen JL, et al. Treatment histories of patients with a syndrome putatively prodromal to schizophrenia. Psychiatr Serv 2002; 53 (3): 342-4
124. Heinssen RK, Perkins DO, Appelbaum PS, et al. Informed consent in early psychosis research: National Institute of Mental Health workshop, November 15 2000. Schizophr Bull 2001; 27 (4): 571-84
125. Heinimaa M, Larsen TK. Psychosis: conceptual and ethical aspects of early diagnosis and intervention. Curr Opin Psychiatry 2002; 15: 533-41
126. Yung AR, McGorry PD. Is pre-psychotic intervention realistic in schizophrenia and related disorders? Aust N Z J Psychiatry 1997; 31: 799-805
127. McGlashan TH, Miller TJ, Woods SW. Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull 2001; 27 (4): 563-70
128. McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res 2001; 51 (1): 47-54
129. Schaffner KF, McGorry PD. Preventing severe mental illnesses: new prospects and ethical challenges. Schizophr Res 2001; 51 (1):3-15
130. Munoz RF, Le HN, Clarke G, et al. Preventing the onset of major depression. In: Gotlib IH, Hammen CL, editors. Handbook of depression. New York: The Guilford Press, 2002: 343-59
131. Gillham JE, Shatte AJ, Freres DR. Preventing depression: a review of cognitive-behavioral and family interventions. Appl Prev Psychol 2000; 9: 63-88
132. Clarke GN, Hawkins W, Murphy M, et al. Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: a randomized trial of a group cognitive intervention. J Am Child Adolesc Psychiatry 1995; 34: 312-21
133. Clarke GN, Hornbrook MC, Lynch F, et al. A randomized trial of a group Cognitive intervention for preventing depression in adolescent offspring of depressed parents. Arch Gen Psychiatry 2001; 58: 1127-34
134. Beardslee WR, Versage EM, Gladstone TRG. Children of affectively ill parents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1998; 31: 1134-41
135. Jaycox LH, Reivich KJ, Gilliam J, et al. Prevention of depressive symptoms in school children. Behav Res Ther 1994; 32: 801-16
136. Beardslee WR, Gladstone TRG. Prevention of childhood depression: recent findings and future prospects. Biol Psychiatry 2001; 49: 1101-10
137. Kumra S, Jacobsen LK, Lenane M, et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998; 37 (2): 221-7
138. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998; 43: 596-604
139. Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8: 151-9
140. Martin A, Landan J, Leebans P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000; 10: 259-68
141. Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002; 41: 1439-46
142. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778-83
143. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25-32
144. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16: 63-74
145. DeGrazia D. Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schizophr Res 2001; 51 (1): 77-86
146. Larsen TK, Johannessen JO, Guldberg C, et al. Early intervention programs in first-episode psychosis and reduction of duration of untreated psychosis (DUP). Schizophr Res 1999; 36: 344-5
147. Lieberman J, Jody D, Giesler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50: 369-76
148. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 9: 5-9
149. DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998; 59 Suppl. 19: 9-17
150. McEvoy JP, Weiden PJ, Smith TE, et al. Expert consensus guidelines series: treatment of schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 12B: 1-58
151. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 Suppl. 4: 1-63
152. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first-episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-7
153. McGorry PD. The detection and optimal management of early psychosis. In: Lieberman JA, Murray RM, editors. Comprehensive care of schizophrenia: a textbook of clinical management. London: Martin Dunitz, 2001: 153-166
154. Davidson L, McGlashan TH. The varied outcomes of schizophrenia. Can J Psychiatry 1997; 42 (1): 34-43
155. Brown GW, Birley JLT. Crisis and life changes and the onset of schizophrenia. J Health Social Behav 1968; 9: 203-14
156. Bebbington P, Wilkins S, Jones P, et al. Life events and psychosis: initial results from the Camberwell Collaborative Psychosis Study. Br J Psychiatry 1993; 162: 72-9
157. Brown GW, Birley JLT, Wing JK. Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiatry 1972; 121: 241-58
158. Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness: a comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976; 129: 125-37
159. Bebbington P, Kuipers L. The predictive utility of expressed emotion in schizophrenia: an aggregate analysis. Psychol Med 1994; 24: 707-18
160. Bebbington P, Kuipers L. The clinical utility of expressed emotion in schizophrenia. Acta Psychiatr Scand Suppl 1994; 382: 46-53
161. Falloon IRH, Boyd JL, McGill CW, et al. Family management in the prevention of exacerbations of schizophrenia. N Engl J Med 1982; 306: 1437-40
162. Leff J, Kuipers L, Berkowitz R, et al. A controlled trial of social intervention in the families of schizophrenia patients. Br J Psychiatry 1982; 141: 121-34
163. Leff J, Kuipers L, Berkowitz R, et al. A controlled trial of social intervention in the families of schizophrenia patients: two-year follow-up. Br J Psychiatry 1985; 146: 594-600
164. Leff JP, Vaughn CE. Expressed emotion in families: its significance for mental illness. London: Guildford, 1985
165. Birchwood M, Spencer E, McGovern D. Schizophrenia: early warning signs. Adv Psychiatr Treatment 2000; 6: 93-101
166. Herz MI, Lamberti S, Mintz J. A program for relapse prevention in schizophrenia: a controlled study. Arch Gen Psychiatry 2000; 57: 277-83.